Hurdles for the Delivery of Multinational Randomized Clinical Trials
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.18503 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Denise van Hout und 23 weiteren Autor:innen. Beteiligte Einrichtung: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: COVID-19, Randomized Controlled Trials as Topic, Multicenter Studies as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Ethical, administrative, regulatory, and logistical (EARL) procedures can hamper clinical trial delivery. Quantification of these hurdles is rare, prohibiting identification of areas for improvement.
Objective
To identify and quantify EARL hurdles in trial delivery before and during the COVID-19 pandemic. Design, Setting, and Participants This cohort study used data from the ongoing Randomized Embedded Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia to enable comparison of EARL procedures for multiple protocols across 19 European countries in the pre–COVID-19 pandemic (February 19, 2016 to March 10, 2020) and COVID-19 pandemic (March 11, 2020, to May 4, 2023) periods. Data were analyzed from November 2024 to March 2025 with contracts and protocol submissions as the units of analysis. Main Outcome and Measures Time to (1) site contract completion, (2) regulatory and ethical approval (TTA), and (3) first patient in (FPI). The UK was compared with non-UK countries because of its distinct research infrastructure.
Results
There were 257 fully signed first contracts with study sites for analysis. In the UK, contract completion times decreased by 97% (95% CI, 95% to 98%), from a median (IQR) of 196 (154 to 250) days in the pre–COVID-19 pandemic period to 5 (1 to 11) days during the COVID-19 pandemic. In non-UK countries, median (IQR) contract completion times were 224 (119 to 412) days and 183 (62 to 291) days before and during the COVID-19 pandemic, respectively (relative difference, −18%; 95% CI, −43% to 52%). In total, 44 interventions in 16 domains were submitted, yielding 232 protocol approvals for analysis. During the COVID-19 pandemic, median (IQR) TTA was 8 (5 to 31) days in the UK and 115 (47 to 103) days in non-UK countries (median difference, 107 days; 95% CI, 76 to 123 days), with large variation across non-UK countries. Time between approval and FPI during the COVID-19 pandemic was, on average, 3 months faster in the UK compared with non-UK countries (median difference, 90 days; 95% CI, 42 to 141 days). Conclusions and Relevance This study found that EARL procedures were lengthy and variable between countries, reflecting different interpretations of trial regulations, with faster processes in the UK. These findings underscore the need to streamline processes across European countries to improve trial efficiency, in particular during future public health emergencies such as pandemics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
- Intensive Care National Audit and Research Centre, London, United Kingdom.
- European Clinical Research Alliance on Infectious Diseases, Utrecht, the Netherlands.
- Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
- Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- Division of Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London, London, United Kingdom.
Zitieren
APA
van Hout, D., Mouncey, P., Harrison, D., Bonten, M., Derde, L., REMAP-CAP European Regional Investigators, Angus, D. C., Anjum, A., Annane, D., Best-Lane, J., Brunkhorst, F., Cecconi, M., Ehrmann, S., Gordon, A., Hays, L. M., Kester, E., Mahon, N., McArthur, C., Nichol, A., …, & Weis, S. (2025). Hurdles for the Delivery of Multinational Randomized Clinical Trials. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.18503
Vancouver
van Hout D, Mouncey P, Harrison D, Bonten M, Derde L, REMAP-CAP European Regional Investigators, et al. Hurdles for the Delivery of Multinational Randomized Clinical Trials. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.18503
BibTeX
@article{vanHout2025,
author = {van Hout, Denise and Mouncey, Paul and Harrison, David and Bonten, Marc and Derde, Lennie and REMAP-CAP European Regional Investigators, REMAP-CAP European Regional Investigators and Angus, Derek C and Anjum, Aisha and Annane, Djillali and Best-Lane, Janis and Brunkhorst, Frank and Cecconi, Maurizio and Ehrmann, Stephan and Gordon, Anthony and Hays, Leanne Marie and Kester, Esmee and Mahon, Niamh and McArthur, Colin and Nichol, Alistair and Peters, Svenja and Pugliese, Sara and Rowan, Kathryn and Torre-Cisneros, Julian and Weis, Sebastian},
title = {Hurdles for the Delivery of Multinational Randomized Clinical Trials},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.18503}
}
EUVIMED